Benign prostatic hyperplasia and its clinical manifestation as lower urinary tract symptoms is a major health concern for aging men. A better understanding of the prostate physiology, function, and pathogenesis has led to the development of number of promising agents.The specific approach used to treat BPH depends upon number of factors like age, prostrate size, weight, prostate-specific antigen level, and severity of the symptoms. 5 -reductase inhibitors decrease the production of dihydrotestosterone within the prostate, which results in decreased prostate volume, improvement of symptoms,...